Clinical Trial Update: A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver [Phase 2]

View source ↗

Summary

A Phase II study of arsenic trioxide (Trisenox) for advanced hepatocellular carcinoma was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Trisenox (arsenic trioxide)

Snippet

Sponsor: The University of Texas Medical Branch, Galveston | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: TERMINATED | Results posted: 2016-02-19